AGM/EGMApr 27, 2026, 04:12 PM
XNCR Seeks Shareholder Approval for Equity Plan Share Increase
AI Summary
Xencor Inc. announced its 2026 Annual Meeting of Stockholders on June 16, 2026, where key proposals include the election of nine directors, ratification of KPMG LLP as auditor, an advisory vote on executive compensation, and a significant amendment to increase authorized shares for its 2023 Equity Incentive Plan by 4,000,000 shares. The company also provided a business update, highlighting encouraging early and mid-stage clinical data for its oncology candidates XmAb819 and XmAb541, and progress in autoimmune disease programs like XmAb942. Xencor reported a strong financial position, ending 2025 with $610.8 million in cash.
Key Highlights
- Annual Meeting on June 16, 2026, to elect 9 directors and vote on 4 proposals.
- Shareholders to vote on increasing 2023 Equity Incentive Plan shares by 4,000,000.
- Proposed share increase represents approximately 5.4% of outstanding shares as of March 31, 2026.
- XmAb819 showed 25% partial response rate and 70% disease control rate in clear cell renal cell carcinoma.
- XmAb541 demonstrated confirmed partial responses in ovarian and germ cell cancers.
- XmAb942 (anti-TL1A) Phase 2b XENITH-UC study initiated for ulcerative colitis.
- Ended 2025 with $610.8 million in cash, cash equivalents, and marketable debt securities.
- Expects to present additional clinical data in H2 2026 for oncology programs.
Price Impact
More from XNCR